LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,092
تعداد مقالات10,022
تعداد مشاهده مقاله27,191,988
تعداد دریافت فایل اصل مقاله7,459,633
Ariafar, Ali, Hasheminejad, Mehrnoosh, Abtahi, Shabnam, Ghaderi, Abbas. (1397). Investigating the Levels of Shed Extracellular Domain of HER2 Protein in the Sera of Bladder Cancer Patients. سامانه مدیریت نشریات علمی, 10(1), 30-36. doi: 10.30476/mejc.2019.44683
Ali Ariafar; Mehrnoosh Hasheminejad; Shabnam Abtahi; Abbas Ghaderi. "Investigating the Levels of Shed Extracellular Domain of HER2 Protein in the Sera of Bladder Cancer Patients". سامانه مدیریت نشریات علمی, 10, 1, 1397, 30-36. doi: 10.30476/mejc.2019.44683
Ariafar, Ali, Hasheminejad, Mehrnoosh, Abtahi, Shabnam, Ghaderi, Abbas. (1397). 'Investigating the Levels of Shed Extracellular Domain of HER2 Protein in the Sera of Bladder Cancer Patients', سامانه مدیریت نشریات علمی, 10(1), pp. 30-36. doi: 10.30476/mejc.2019.44683
Ariafar, Ali, Hasheminejad, Mehrnoosh, Abtahi, Shabnam, Ghaderi, Abbas. Investigating the Levels of Shed Extracellular Domain of HER2 Protein in the Sera of Bladder Cancer Patients. سامانه مدیریت نشریات علمی, 1397; 10(1): 30-36. doi: 10.30476/mejc.2019.44683

Investigating the Levels of Shed Extracellular Domain of HER2 Protein in the Sera of Bladder Cancer Patients

Middle East Journal of Cancer
مقاله 5، دوره 10، شماره 1 - شماره پیاپی 37، فروردین 2019، صفحه 30-36    اصل مقاله (210 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2019.44683
نویسندگان
Ali Ariafar* 1؛ Mehrnoosh Hasheminejad2؛ Shabnam Abtahi2؛ Abbas Ghaderi2
1Urology-Oncology Research Cent er, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Receptor tyrosine-protein kinase ERBB2, also known as human epidermal growth factor receptor-2 (HER2), is heterogeneously expressed in a variety of human cancers, including bladder cancer. Based on previous studies that show its association with bladder cancer progression, HER2 has been included in novel multiplatform biomarkers for prediction of bladder cancer prognosis. However, the clinical significance of HER2 status remains underinvestigated and poorly linked to the patients’ clinicopathological features. Here, we aim to scrutinize the levels of the extracellular domain of HER2 in the sera of bladder cancer patients and correlate these levels with clinicopathological features of the tumor.Methods: In the present analytical cross-sectional study, we enrolled 60 pathologically confirmed bladder cancer patients along with 20 age-sex matched healthy controls, and compared their serum HER2 levels as measured by enzyme-linked immunosorbent assay.Results:We observed no statistically significant difference when comparing the levels of HER2 in the sera of cases and controls (P>0.05). Interestingly, serum HER2 levels of controls were higher than bladder cancer patients who had lymph node metastasis (P=0.036). Serum levels of HER2 were also higher in controls than bladder cancer patients with perineural invasion (P=0.028). We observed significantly higher HER2 serum levels in transitional cell carcinoma patients in comparison to non-transitional cell carcinoma patients (P=0.016).Conclusion: Our observations are suggestive of the absence of any association between bladder cancer prognostic factors and serum HER2 levels. To draw any definitive conclusion, further studies with larger sample sizes that examine the presence of neutralizing auto-antibodies against serum HER2, immunohistochemistry examination of HER2 in bladder tumor and lymph node samples, and urinary HER2 levels, along with measurement of its serum levels would be helpful.
آمار
تعداد مشاهده مقاله: 2,185
تعداد دریافت فایل اصل مقاله: 889


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب